The cancellation of 36 certification items affected many medical personnel

On April 28, the State Administration of Pharmaceutical Supervision issued the Notice on the Cancellation of 36 Certificates (No. 34, 2019). The State Drug Administration has decided to cancel 36 certification items in accordance with the requirements of the Notice of the General Office of the State Council on Cleaning up Certificate Matters, in order to further reduce certification for the convenience of the people and optimize services.
Since the date of publication, the certification items set forth in the normative documents listed in the Annex have ceased to be executed. If the certification matters set forth in the regulations of the departments listed in the annex involve revision of the rules of the departments, the implementation of the rules shall be stopped after revision of the rules of the departments according to the procedures. 36 items of certification include 14 items of "certification matters for the establishment of normative documents" and 24 items of "certification matters for the establishment of departmental regulations". Many things, no longer require applicants to submit this, instead of network verification. It involves many aspects, such as drug production license, licensed pharmacist registration certificate and so on.
Looking for chemical products? Let suppliers reach out to you!
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
6th Drug Safety Symposium 2026 to Focus on “Beyond Algorithms & Assumptions, What Actually Matters in Pharmacovigilance”
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Two departments issued a document to guidethe strengthening of drug cases investigation and handling
-
National Health Care Commission: 50% of thecountry's public hospitals above the second level have carried out appointmentdiagnosis and treatment services
-
India starts testing a pharmaceuticalcompany's exports of cough syrup
-
Inmanar Announces Several BreakthroughSequencing Innovations
-
China's medical supplies supply securitycapabilities continue to enhance
-
244 medical device concept stocks roseindustry insiders said the process of domestic replacement is expected toaccelerate
-
Rare diseases pose a challenge to thepharmaceutical industry
-
Pfizer's $11.6 Billion Double-acting Migraine Drug Generates $318 Million in First-half Revenue
Recommend Reading
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
Supply and Demand Costs Resonate, Polyethylene Weakens in Short-term Fluctuations
-
Bridgestone Reports Q3 Growth Amid Challenging North American Market
-
BASF’s Zhanjiang Integrated Site Commissions New Neopentyl Glycol (NPG) Unit
-
Raw Materials Soften, Consumption Sluggish—PC Prices Fall from High Levels
-
Acetophenone: Properties, Uses, and Applications